stockrowXencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Shares outstanding
Xencor, Inc.'s shares outstanding at the end of fiscal 2025 was $74.2M, up 14.1% from $65.0M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $75.9M. Over the past ten years it has ranged from $39.0M (fiscal 2015) to $74.2M (fiscal 2025) — the current reading is the highest in ten years. Xencor, Inc. ranks 200th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $74.2M | 14.14% |
| FY2024 | $65.0M | 7.50% |
| FY2023 | $60.5M | 1.43% |
| FY2022 | $59.7M | (1.39%) |
| FY2021 | $60.5M | 5.74% |
| FY2020 | $57.2M | (2.15%) |
| FY2019 | $58.5M | 8.39% |
| FY2018 | $53.9M | 15.22% |
| FY2017 | $46.8M | 10.45% |
| FY2016 | $42.4M | 8.65% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $75.9M | 0.81% |
| Mar 2026 | $75.2M | 1.36% |
| Dec 2025 | $74.2M | (0.23%) |
| Sep 2025 | $74.4M | 0.18% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RXRX Recursion Pharmaceuticals, Inc. compare | $543.0M |
| ADMA ADMA Biologics Inc compare | $225.8M |
| RCUS Arcus Biosciences, Inc. compare | $127.4M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $124.1M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | $111.7M |
| BEAM Beam Therapeutics Inc. compare | $104.7M |
| XNCR Xencor, Inc. | $75.9M |
| PHVS Pharvaris N.V. compare | $68.1M |
| MBX MBX Biosciences, Inc. compare | $47.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement